Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
the TRUTH of AMBS and the CEO Blog content is not about who sponsored it
trying to diffuse, distract, distort and fabricate false narratives ain't going to work for you anymore Redspudder
we're on to you and your ilk brah...!
besides, if I were the twice failed hack wannabe "Financial Engineer" Stanford University grad AMBS CEO...
I too would want the AMBS CEO Blogs taken down permanently from the WWW internet
uh Ohhhh - well well well - lookie here Mr Redspudder - all distortions of reality and facts
and the false narrative and protection of a catastrophic failure CEO
with the help of YOU the infamous Back Office Promo Boy pumpers, shills and touts:
oh and here are some really good MANF CEO Blog pieces - for "entertainment purposes" only (of course)
read em and weep - cause this is what the TRUTH is about - and is absolutely NOTHING of what you say:
_____________________________________________________________________________________________
01.) MANF: Arresting Cell Death in PD, TBI, Cardiac Ischemia & More
December 10th, 2012
Innovation is difficult and risky. In biotechnology, you can add long and expensive to the list of challenges. On the upside, with the right technology and strategy, biotechnology innovations have the power to improve and prolong the lives of millions of people who suffer from disease, while generating revenues and value for shareholders.
Here at Amarantus, we are innovators in the field of Programmed Cell Death, also known as Apoptosis. Our lead drug candidate (Mesencephalic-Astrocyte-derived Neurotrophic Factor) MANF is a first-in-class therapeutic protein that mitigates apoptosis by improving the protein-folding process inside the cell. MANF is currently in pre-clinical development for a range of indications. Our primary focus is on developing MANF as a new disease-modifying treatment for Parkinson’s disease. We also have programs in Traumatic Brain Injury and Cardiac Ischemia, and have initiated an effort to identify a suitable orphan drug indication to pursue MANF’s further development. Because MANF acts at such a fundamental cellular level, it is likely to have applications across a broad range of currently unaddressed disease indications.
Amarantus management has been following the evolution of the biopharmaceutical space and we’ve developed our business model around important themes that are reshaping the way innovative products get developed in this new economy. Below are what we believe to be the most important trends in the industry:
1. Technology is not enough; you must build a business. We are focused on building a business, not a science project. To that end, we are evaluating complementary therapeutic assets in mid-stage clinical development to add to our pipeline to reduce time to market as we prepare for a national exchange up-listing. MANF is the centerpiece of our business, and we believe we can attract strong assets around it because of MANF’s vast potential. To this end, the Company has attracted a world-class team of advisors to give us the expertise to guide our business direction and diversify our pipeline.
2. Intellectual property is what big companies are willing to pay for. Our patent portfolio around MANF is extensive and robust. We recently won a patent challenge to our key intellectual property in Europe where the courts asserted that our IP covered not only MANF, but also proteins that closely resemble MANF. We are in a very strong negotiating position with any company that wants access to MANF.
3. Targeted medicines are what regulators are looking for. Amarantus in-licensed a clinical-stage Parkinson’s diagnostic program called NuroPro that will gives us a competitive advantage as we seek to prove that MANF has a ‘disease-modifying’ effect in Parkinson’s. This approach separates Amarantus from competitors because we are focusing on both therapeutics and diagnostics to help manage the disease.
4. Today’s business model is about partnerships. We have developed a partnering business model that is based on the belief that we must maximize our internal strengths, while leveraging the strengths of partners to best achieve our objectives. In order to maximize potential returns, the Company is establishing its partnership criteria with our advisors as we look at near-term value inflexions to achieve further value-building milestones.
In closing, this is a very exciting time for Amarantus. We just completed our first institutional capital raise and have attracted Big Pharma talent to our Advisory Board. We have data coming shortly on our MANF Parkinson’s program and expect additional corporate milestones will be reached in the coming weeks. As we achieve these milestones, we believe we will be in a good position to up-list to a national exchange. Most importantly, we are looking to bring hope to millions of patients and their families who suffer from the debilitating diseases MANF has the potential to treat. We strongly believe this strategy will build long-term shareholder value.
I thank you for taking the time to read this letter and looking forward to communicating with you in the future.
Gerald E. Commissiong
President & Chief Executive
_____________________________________________________________________________________________
07.) Ophthalmology: MANF’s Orphan Strategy Coming into Focus in Retinitis Pigmentosa
Posted on August 14th, 2013
MANF continues to perform on so many different levels for Amarantus. While the recent focus has been on the Company’s nearer-term product candidate LymPro, it is critically important to remember the vast potential of our MANF program. What I find most remarkable about the sheer breadth of the Company’s lead therapeutic program is that, in the end, all of its potential applications to treat diseases in various organs throughout the body, including the brain, heart, and most recently the eye, are based on the exact same fundamental biological mechanism: mitigating apoptosis.
Retinitis Pigmentosa (RP) is a chronic progressive degenerative disorder of the eye that is characterized by the death of photoreceptor cones and rods in the retinal pigment epithelium (RPE). It is a genetic disease that affects roughly 100,000 people in the United States, 100,000 people in Europe and 50,000 people in Japan. Due to its relatively small patient population, RP qualifies as an orphan indication which provides a number of financial incentives for development of MANF in this indication. Further, there is a very significant unmet medical need as few therapies effectively treat this population of patients, leaving most legally blind before they reach the age of 50. Moreover, delivery of MANF directly into the eye is far simpler than Convection Enhanced Delivery in Parkinson’s, or systemic delivery in Ischemic Heart Disease. Together, the components of a smaller patient population, a significant unmet medical and a local delivery need may provide an ideal opportunity for the rapid clinical development of MANF that could lead to commercialization years ahead of larger indications for MANF.
We believe RP is just the beginning of the MANF story in ophthalmology. Other neurotrophic factors have begun to show promise in many diseases in the area and the data announced earlier this week scientifically supports development in many therapeutic indications beyond RP in ophthalmology, including Dry Age-Related Macular Degeneration (Dry AMD). Dry AMD affects approximately 15 million people in the United States. 14%-24% of the U.S. population age 65-74 years and 35% of people aged 75 years or older have the disease[1]. Currently, there are no available disease-modifying treatments for Dry AMD, making the opportunity for MANF so attractive. MANF’s development in RP may accelerate the pathway for it to reach the significantly larger Dry AMD patient population by proving cone and rod protection in humans in the smaller RP population first.
Ophthalmology has taken on significantly greater interest as of late from major players in the biopharmaceutical industry: Pfizer Inc. (PFE), Allergan Inc. (AGN), Alcon Inc. (ACL), Novartis AG (NVS), Merck & co. Inc. (MRK) and Roche (RHHBY) cover approximately 70% of the $10 billion market. The primary reason why the ophthalmology market is currently so small is very simple: very few effective disease-modifying treatments exist. Interestingly, the FDA notes that only 21 new drugs were approved in the last 10 years, suggesting a significant lack of breakthrough biology in this space, as evidenced by these companies’ thin ophthalmology pipelines. What’s more, these companies have primarily added drug candidates to their pipelines through in-licensure and strategic transactions, making the opportunity even more appealing for Amarantus. There is no question that the medical outcome of new, truly disease-modifying treatments in the area will have a meaningful impact on patients’ lives; being able to see versus being blind is a massive improvement in quality of life that would undoubtedly be highly coveted by patients, caregivers and physicians.
As we continue our pursuit of identifying a variety of orphan indications for MANF, this first success is a major milestone. When data becomes available in the coming weeks on different applications, we will begin to spend some time reprioritizing our MANF pipeline to ensure that we are maximizing shareholder value, while simultaneously ensuring that we are expeditiously moving MANF forward in the various indications where MANF has shown benefit pre-clinically. We intend to rely heavily on not-for-profit funding for certain indications in order to minimize shareholder dilution while maximizing patient benefit as we move MANF forward. The economies of scale created by having a single therapeutic candidate treat multiple diseases cannot be overstated, as development milestones in one area support further development in the others. The Company’s orphan drug strategy outlined in November of 2012 is beginning to bear fruit and we intend to pursue orphan diseases aggressively as we see this as the most effective and expeditious route to getting MANF to patients.
A prime example of a successful orphan strategy is Genzyme, which was acquired by Sanofi Aventis (SNY) in 2011 for $20.1B. Another example of a successful orphan strategy is FerroKin Biosciences, which was acquired by Shire (SHPG) for $325M in early 2012 with only $27M in paid-in-capital and a virtual staff of 7 employees. In 2011, Alexion Pharmaceuticals (ALXN) reported $783M in revenue based on sales of its only product Soliris, a drug that treats a population of approximately 10,000 patients in the US and Western Europe.
We have taken a very important step forward in our MANF program and strategy and are looking forward to updating shareholders on further developments in the weeks and months ahead.
Thank you for taking the time to read this blog.
Gerald Commissiong
President & CEO
_____________________________________________________________________________________________
18.) MANF Continues to Deliver Heading into 2H-14
June 30th, 2014
Looking back on the last two years, it is amazing to see how the MANF story has unfolded in conjunction with the other corporate initiatives the Company has undertaken including the addition of LymPro and Eltoprazine to our pipeline. The effort to diversify our pipeline was largely initiated to allow the Company’s scientific team to uncover MANF’s true value by identifying market opportunities with the highest net present value, which in biotechnology generally means fastest path to market in an orphan indication. That strategy bore fruit in the middle of 2013, when the Company identified in scientific literature a reference to MANF’s utility in Retinitis Pigmentosa (RP) from the University of Miami’s Bascom Palmer Eye Institute and later secured the intellectual property surrounding that finding. With an exclusive option agreement in hand, the Company has the necessary footing to make further investments in prosecuting MANF’s full potential in RP. Now midway through 2014, the Company is in the process of executing a methodical plan to deliver on the potential for MANF in RP, as well as continuing to expand with data the underlying scientific principles supporting MANF into new areas of research creating valuable intellectual property and know-how. Some of the key steps completed thus far include:
1. The Company has received interim data and is awaiting final results for functional assessments for MANF from a leading contract research lab with specialty in RP rodent models;
2. The Company has received interim data and is awaiting final results for toxicology safety assessments for MANF from a leading contract lab with specialty in rabbit ophthalmological models;
3. Researchers at the University of Miami have completed running additional experiments for MANF in functional models of RP, and expect their findings to be published in peer-reviewed journals in the near future;
4. The Company has received the final report from a leading contract research lab evaluating MANF’s activity in a tau hyperphosphorylation model of Alzheimer’s disease (AD). This study was conducted to confirm work previously published in a Chinese journal;
5. The Company has identified a number of significant independent peer-reviewed research papers published in Chinese journals confirming previously published Western data, as well as identifying new uses for MANF;
6. The Company has sourced contract manufacturing organizations capable of commercially manufacturing MANF, completed our due diligence and we expect to select a manufacturer in the third quarter.
All of the interim results we have seen to date in ophthalmology have been positive, which gives us a great deal of confidence heading into the second half of the year that RP will be the first of several INDs for MANF. All of the data being produced will be supportive of additional ophthalmological indications, including Wolfram’s-induced blindness which we are pursuing with Dr. Urano from the Washington University School of Medicine. Beyond these updates, the Company is establishing additional research collaborations with leading institutions in new and potentially groundbreaking areas, as well generating new IP surrounding the use of MANF in these various indications in the third quarter. We will be delivering the confirmatory AD results to the market very shortly, which in turn raises interesting prospects vis-a-vis our LymPro blood test for Alzheimer’s disease. When we first in-licensed LymPro, we had no idea that MANF could have an impact on aspects of the underlying pathophysiology of AD. However, with recently published data linking tau mis-folding to cell cycle dysregulation and amyloid aggregation, the prospect of MANF becoming the basis for new treatments in AD has become extremely interesting. Reproducibility is the hallmark of good science, and to date MANF has reproducibly demonstrated activity consistent with a breakthrough treatment across a highly valuable spectrum of indications. In addition, we are nearing the completion of the sourcing process necessary to retain our regulatory consulting group with expertise with a specialty in the area of ophthalmology to assist us in the filing of orphan drug designation with the FDA and EMA for MANF in RP. Based on the timelines and estimates we have received, we expect to submit to the FDA and receive a reply regarding our submission in the second half of this year, within the same time frame that we will be looking to up-list our common stock to a national exchange.
Last week we attended a successful BIO convention where we ended up participating in over 60 partnering meetings, and were extremely pleased with the reception we received from the community at large. It is clear that we have become highly visible to larger pharmaceutical companies, as well as promising early-stage companies seeking to partner their assets. The general theme was that each of our assets has tremendous promise within their own right, and most importantly that there is a strong scientific and business case to be made for each becoming a blockbuster asset. Taken together, the synergies created from a business perspective are able to insulate the Company from significant enterprise risk, and our ability to demonstrate progress with any of these assets will lend credibility to the rest of the portfolio. In light of these comments, we are now especially looking forward to the month of July which includes AAIC and our #C4CT Summit, as well as the rest of 2014. We believe the Company is growing stronger by the day and we are excited to share our enthusiasm with our fellow shareholders.
I thank you for taking the time to read this blog and look forward to updating you on additional progress for the Company as we achieve our true potential.
Warmest Regards,
Gerald E. Commissiong
President & CEO
_____________________________________________________________________________________________
25.) Eltoprazine, LymPro and MANF: The Path Forward to Value Creation
Oct. 27th, 2014
The last several weeks have been a particularly exciting time for the team at Amarantus. Months of effort are beginning to bear fruit, as we’ve begun to reach milestones in all three of our key programs. As the company continues to make systematic progress in executing on our business plan, we are encouraged by the reception we are receiving from patients, physicians and shareholders who understand the importance of what we are doing. I’ve begun to receive many inquiries recently about our most advanced therapeutic program, Eltoprazine, following the announcement of our first interaction with the FDA. Given the imminent Phase 2b Parkinson’s disease clinical trial initiation, I’d like to take this opportunity to put some context to each of our programs so that there is a better understanding of their current status and what is before us in the weeks and months ahead, as many new prospective shareholders have been asking what our strategy is for each program going forward.
Eltoprazine is the company’s most classical asset from a pharmaceutical industry perspective. It is an orally administered, small molecule drug candidate, which selectively activates specific serotonin receptors in the brain. We are currently developing it for Parkinson’s disease Levadopa-induced dyskinesia (PD LID) and adult attention deficit hyperactivity disorder (Adult ADHD). Eltoprazine was originally developed by Solvay Pharmaceuticals for the treatment of aggression in multiple psychiatric conditions. Throughout its clinical development history, Eltoprazine has been administered to nearly 700 healthy subjects and patients, hence providing a sound body of safety data to support further development.
Amarantus holds all filed regulatory dossiers in the United States and Europe, and has an exclusive license to the key intellectual property covering Eltoprazine’s use in PD LID and Adult ADHD. Our license covers method of use patents issued for Eltoprazine in North America and Europe giving coverage for Eltoprazine through the middle of 2022, as well as method of use patent applications for PD LID filed in 2012 potentially giving coverage through 2027. Eltoprazine is eligible to receive post-approval marketing exclusivity of 5 years in the United States and 10 years in Europe under the New Chemical Entity (NCE) regulatory approval pathway.
Parkinson’s disease Levodopa-induced Dyskinesia (PD LID)
Initial proof-of-concept data for Eltoprazine in PD LID were obtained in a Phase 2a study supported by the Michael J Fox Foundation (MJFF). These data were presented at a MJFF meeting in 2012 and at the OneMedForum 2014 conference in January of this year and a manuscript of the study has been submitted for publication to a major a peer-reviewed Neurology journal. In the meantime, our therapeutics division clinical development team has been diligently preparing for the initiation of a Phase 2b study in PD LID in the United States and in Europe. We are looking forward to receiving pre-IND feedback from the FDA later in the fourth quarter and being able to open a new IND in the Neurology Division of FDA shortly thereafter. The Phase 2b trial is on schedule to start in early 2015. There is a big unmet medical need for PD LID drugs. So far, there are no products specifically approved for this indication. There is a strong desire among clinicians, patient advocacy groups and regulators to see drugs approved for the treatment of LID, which would markedly improve the quality of life for patients with PD.
Apart from its potential for treating PD LID, we see substantial opportunities for Eltoprazine in other aspects of PD that would enhance the product lifecycle management, increase its market share and therefore potentially substantially increase its value. Non-motor symptoms that include mood disorders, cognitive deficits and impulse control disorders, are an important part of advanced PD that are poorly addressed by current treatments. The clinical data we already have in more than 350 psychiatric patients support a potential utility of Eltoprazine in the treatment of non-motor symptoms of PD, thereby creating an exciting opportunity to expand the clinical development into additional indications in PD patients.
We have seen recent successes by other companies in the PD space provide tremendous value for shareholders when treating PD symptoms, and we believe Eltoprazine positions Amarantus to follow on a similar path.
Adult Attention Deficit and Hyperactivity Disorder (Adult ADHD)
Recent increased interest in the market’s need for new, non-scheduled ADHD drugs has highlighted the importance of Eltoprazine’s positive clinical data in the area of Adult ADHD, where the market seems to be growing rapidly in comparison to pediatric ADHD as many pediatric ADHD patients mature into adults. We previously outlined our intentions to initiate a Phase 2b trial for Eltoprazine in Adult ADHD following the initiation of the Phase 2b PD LID clinical trial, and we remain on track to achieve this as much of the groundwork for the Adult ADHD trial is being completed for the Phase 2b PD LID trial. Of note, the clinical data obtained in the Phase 2a Adult ADHD suggest that Eltoprazine has clinically significant activity across a broad spectrum of Adult ADHD patients including both the Primarily Inattentive (“PI”) subgroup, as well as the Hyperactive subgroup.
A copy of the summary of the clinical data for Adult ADHD data is available online at: http://www.sec.gov/Archives/edgar/data/1424812/000114420414005562/v367098_ex99-1.htm.We believe Eltoprazine could eventually be used to treat Pediatric ADHD in addition to Adult ADHD. With its novel mechanism of action in this area, and potential applicability to a variety of patient subtypes, we see an important market potential for Eltoprazine in ADHD. This condition affects over 58 million people worldwide, and the key unmet medical need in this indication is for non-scheduled, non-stimulant drugs, such as Eltoprazine.
We firmly believe Eltoprazine will generate significant value for the company as we continue its further development, especially given its extensive drug profiling while at Solvay. Combined with data emerging from our planned studies, we believe there will be significant interest from the pharmaceutical industry as our trials advance in 2015. The company intends to be active in business development for this asset.
LymPro is our most advanced program, given that it is set to be commercialized in the very near future. We are on track to bring LymPro to market for the Research Use Only market in the fourth quarter, primarily targeting pharmaceutical clinical trials, and will be submitting to CLIA shortly thereafter for widespread commercial use. LymPro demonstrated very high specificity and sensitivity for Alzheimer’s disease detection in severe and moderate patients in our recently announced LP-002 bridging study, and we are looking forward to additional data in early-stage Alzheimer’s this quarter from an extension of the LP-002 study to support additional intended-use statements under CLIA for LymPro. The company is currently preparing marketing materials to support the launch to both the pharmaceutical industry and the general practitioner community to ensure they understand the value that LymPro will bring to their diagnostic paradigms. In addition, the company is continuing the development of its reimbursement strategy to support commercial sales, in addition to putting in place its LymPro general marketing strategy. We believe putting all of the pieces in place for a successful launch of LymPro is crucial to its initial launch and establishment as the market leading blood diagnostic for Alzheimer’s disease. We intend to publish the LymPro data in a peer-reviewed journal following study completion.
As the launch of LymPro nears, the company is also looking to maximize the value of the investment we have made in the asset since acquiring it in late 2012. As a holding company, Amarantus is continuing to evaluate methods of returning value to shareholders, including a potential spinoff of the company’s diagnostic division. In addition to LymPro and our NuroPro Parkinson’s diagnostic, we are actively evaluating additional complementary late-stage neurology-focused diagnostic assets that would bolster our diagnostic division and make for a successful ‘spin-out’ while concurrently returning value to our shareholders. We believe we will be able to execute on this strategy in the near-term.
As a holding company, our strategy is to acquire undervalued assets, incubate them through critical de-risking milestones and thereafter seek to deliver value to our shareholders through strategic initiatives. We believe we are well positioned to deliver on that promise in the near-term with our diagnostic division, making for the first data point of success of the overall business model and positioning Amarantus to continue this model as we move forward. We believe wholeheartedly in LymPro, and want to ensure that it receives the necessary management focus and commercialization expertise for it to become the gold standard for Alzheimer’s diagnosis. We expect to have updates on this initiative in the near-term.
MANF continues to deliver. In the last year, we have strategically shifted the development focus of MANF towards ophthalmology, where we see significant opportunity to generate value in the near-term. MANF recently was shown to be efficacious in two additional Retinitis Pigmentosa models, as well as delivering positive data in a model of ocular ischemia which supports development in a number of indications, including Central Retinal Vein Occlusion (CRVO), Central Retinal Arterial Occlusion (CRAO) and Glaucoma. We also have experiments ongoing evaluating MANF’s efficacy in Wolfram’s Syndrome with Washington University in Saint Louis. We recently applied to the FDA for orphan drug designation for MANF in Retinitis Pigmentosa and expect additional orphan filings in the near future in the area of ophthalmology. We expect to initiate GMP manufacturing for MANF this quarter to support multiple IND filings for MANF in various indications. For those of you who are new to the MANF story, MANF has demonstrated efficacy in various animal models of human disease, including:
1. Retinitis Pigmentosa
2. Ocular Ischemia (CRVO, CRAO and Glaucoma)
3. Parkinson’s disease
4. Diabetes
5. Cardiovascular Ischemia (Myocardial Infarction)
6. Cerebral Ischemia (Stroke, Epilepsy)
A select list of peer-reviewed publications for MANF is available on our website at: http://ir.amarantus.com/scientific-publications
This is an impressive list of potential indications. We are currently focusing the majority of our efforts in the ophthalmological areas, however we see significant value in strategically advancing proof of concept animal work in these and other areas as MANF approaches first-in-man studies in orphan ocular indications. We continue to believe that MANF could be one of the big successes in biotechnology due to its unique mechanism and will diligently shepherd the MANF Program through de-risking milestones on its path to treating patients. We are very, very excited about MANF and what lies ahead.
In Closing we are continuing to evaluate new opportunities for the company that we believe will add significant value to our pipeline outside of our current areas of focus. As we expect to soon derive value from our diagnostics division, we believe it will be important to replenish our pipeline with strategically positioned programs that have the potential to deliver significant return on investment for the company, as LymPro has. We believe Eltoprazine is also well positioned to replicate that model, and believe the value created by both of these assets will further support MANF’s development. As a biotechnology holding company, we have the luxury of being strategically diversified in highly attractive areas of growth across our pipeline. With this strategy we are insulated from enterprise risk from any one program, thereby giving us leverage as we look for additional product opportunities and allowing us to return value to our long-term shareholders either through equity gains or dividends.
Alzheimer’s disease, Parkinson’s disease and blindness are devastating disorders that can leave families, caregivers and patients reeling from damage left in their path. Being able to impact each of these conditions delivers a sense of great pride to our employees that we hope you share as shareholders. I thank you for taking the time to read this blog, and look forward to communicating with you regarding our progress on many of the points discussed above later this quarter.
Warmest regards,
Gerald E. Commissiong,
President & CEO
_____________________________________________________________________________________________
can't help it if you keep walking into the TRUTH....
but only wish to distort it - for personal reasons - from behind the veil you hide behind
hmmm - wonder why that is....???
here's to you - shill, tout and tool "Redspudder" - and your failed pumping endorsements of AMBS TOMDF VERB and many others:
"the truth will set you free" - you should try it some time "Redspudder"
SMH - sad but true
AJMHO
oh Mr Redspeed or is it Redsputter...?
I have no problem standing behind my name or my reputation - anywhere - anytime - under any circumstance
how bout you - how bout you and your Back Office Promo Boy wrecking crew posting your true ID's - if you want to be taken seriously
instead of hiding like "little boyzzz" with fake mustaches behind your keyboards all these years...?
other than that - you and your "pumping posse" are nothing more than phonies, shills, spooks, and touts
threatening well established and credible posters with law suits
how imbecile and moronic can you get:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172469943
you and your ilk JoeyForkitBollo, GreesieMonkee, Gman, Wordie, Rocky57, Maui, and few others have have been exposed for who you truly are:
SMH - nuff said
MOO hooie
yeah keep buying dem TOMDF lotto tickets
maybe you and the Back Office TOMDF Promo Boy pumpsters can wrestle up a few more unsuspecting novice investors
you know - to chip in and get this sham to 3-Bil. in the float - yikes
now wouldn’t that be kewel….?
SMH - Gerald loves yah brah - nuff said
MOO fakery
hey Mr Redspud and his doomed reputation in tow
looks like LPC is so much better than the Astoria Queens financial mafia that the twice failed hack wannbe TOMDF flunkie CEO uses, eh Redsputter...?
or maybe even that VERB catastrophe and their toxic's you were pumpin and loosing on not so long ago, eh...?
in Josh we trust...!
SMH - sad and pathetic - reputation shot - nuff said
anyone listening to you should get their head examined
MOO goosie
well well well - a TOMDF a Lotto Play now...?
no surprise there - not with Gerald Commissiong - illusion creator, serial diluter, hack, Stanford Univ. "Financial Engineer", twice failed wann-be CEO, and his Astoria Queens financial mafia - toxic spiral death convertible debt associates...
well this is all wrong - not with 3-Bil. OS and 2.7-Bil. already out on the street and 300-Mil. more left to dilute...
but you know what JoeyForkitBollo (anonymous multiple pizza delivery guy prankster and family personal info disseminator) ... I hope you and all the rest of the TOMDF emaciated shareholders are able to get this POS scam security back over $0.01 and salvage your "catastrophic" averaged down losses here as well - and the reason why I am wishing you and the rest here good fortune - is because I'm a good guy - and someone who got taken by Gerald myself with a breached agreement - and knows the truth about Gerald and his ilk....
nuff said - peace out...!
could also involve a potential ticker change
which changes your calculus…!
just sayin …
BAF MONI
well spoken
and a word to the wise - but there's not that many wise 'back office promo boyzzzz' here
as those boyzzz are all on a mission to make GC rich
with his ginormous $760k/yr annual salary - plus perks, benefits, speaker fees, travel expenses, retirement accounts, etc...
all at the expanse of the novice and unsuspecting investor
SMH - ain't that right...?
MOO voodoo
need some action from the sidelines
end of day - day trader sell off - followed by small buys
ho hum
BAF MONI
where’s Riggs ….?
DB ain’t cuttin it
let’s momo MONI into the $0.05’s
BAF
TOMDF PR's much - lookie here...
and not one with any significant value or revenue to it whatsoever:
Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients
Aug 30, 2023 8:19am EDT
Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics
Mar. 28, 2023
Todos Medical Begins Trading on the OTC Pink Marketplace
Mar. 27, 2023
Todos Medical Supports Long COVID Awareness Day
Mar. 15, 2023
Todos Medical Enters Into Moratorium on Conversions Agreement With Convertible Note Holders
Mar. 13, 2023
Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics
Feb. 14, 2023
Todos Medical to Present at the RHK 2022 Disruptive Growth Conference
Dec. 06, 2022
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
Nov. 29, 2022
Todos Medical to Attend World Antiviral Congress
Nov. 22, 2022
Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network
Nov. 16, 2022
Todos Medical Terminates Tollovid™ Products License & Distribution Agreement with T-Cell Protect Hellas S.A.
Nov. 10, 2022
Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for MonkeyPox PCR Test to US FDA
Oct. 14, 2022
Todos Medical Announces Successful Pilot Launch of Suite of PCR Testing Services by CLIA/CAP Lab Provista Diagnostics
Oct. 06, 2022
Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform
Sep. 30, 2022
Todos Medical Announces USPTO Trademark Notice of Allowance for 3CL Protease Biomarker Diagnostics TolloTest™
Sep. 27, 2022
Todos Medical Enters Into $50M Contract to Supply Tollovid™ and CBD Products to Retail Distributor Company Nerd Hemp
Sep. 22, 2022
Todos Medical Announces NFL Hall of Famer Michael Irvin as Tollovid™ Sports Ambassador for #TolloUp Campaign
Sep. 16, 2022
Todos Medical Announces Preprint of Long COVID Case Study Participant with Confirmed Microclot and Hyperactivated Platelets who Benefitted from Tollovid
Sep. 15, 2022
Todos Medical & The Alchemist’s Kitchen to Host “Long COVID: An Integrated Approach” Event Benefitting Survivor Corps
Sep. 13, 2022
Todos Medical’s 3CL Protease Inhibitor Supplement Tollovid™ Featured in Wellness Magazine
Sep. 13, 2022
Todos Medical Partner NLC Pharma Assigns IP for Tollovir™, Tollovid™, and TolloTest™ into JV 3CL Pharma
Sep. 12, 2022
Todos Medical CEO Discusses Long COVID Economic Impact with Moneta Advisory Managing Partner Marc LoPresti
Sep. 09, 2022
Todos Medical Announce Kingcarlx as Brand Ambassador for the Tollovid #TolloUp Lifestyle Campaign
Sep. 02, 2022
Todos Medical Establishes Botanical Supplement Manufacturing Capabilities to Support Tollovid Global Expansion and Initiates CBD-A Production
Aug. 31, 2022
Todos Medical Expands COVID Onsite School Sample Collection to Include MonkeyPox Testing
Aug. 29, 2022
Todos Medical Announces Saliva-Only MonkeyPox Testing at CLIA/CAP Clinical Lab Provista Diagnostics
Aug. 26, 2022
Todos Medical Enrolls Female Long COVID Patient Unable to Secure Testing While Symptomatic for MonkeyPox into Provista Diagnostics Case Study Series
Aug. 25, 2022
Todos Medical Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women
Aug. 23, 2022
Todos Medical Announces Commercialization of Lesion and Saliva-Based MonkeyPox PCR Testing
Aug. 22, 2022
Todos Medical Announces Preprint of Data from First 100 Participants in IRB-waived Market Research Study of Supplementation with Tollovid in Long COVID
Aug. 19, 2022
Todos Medical Reports Pre-Print of Publication Detailing Tollovid Supplementation Following COVID-19 mRNA Vaccination in Long COVID
Aug. 15, 2022
Todos Medical Completes Trial Design for Tollovid™ Long COVID Clinical Study in Adults
Aug. 11, 2022
Todos Medical Announces PCR Validation of Wound and Respiratory Pathogen Panels at CLIA/CAP Lab Provista Diagnostics
Aug. 10, 2022
Todos Medical Announces First Two Contracts for PCR-based MonkeyPox Testing at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
Aug. 08, 2022
Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics
Aug. 05, 2022
Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
Aug. 03, 2022
Todos Medical Announces Preprint of Acute COVID-19 Paxlovid Rebound Rescued by Tollovid
Aug. 01, 2022
Todos Medical Partners with Amerimmune Diagnostics on Long COVID Biomarker Panel
Jul. 28, 2022
Todos Medical Announces Preprint of Chronic Long COVID Case Study #8 of Paxlovid® Treatment Followed by Tollovid™ Dietary Supplementation
Jul. 22, 2022
Todos Medical Reports Case Study #7 in Acute and Long COVID
Jul. 12, 2022
Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients
Jun. 30, 2022
Todos Medical Releases Preliminary Data From IRB-Waived Tollovid® Market Research Study in Acute and Long COVID
Jun. 23, 2022
Todos Medical Retains Moneta Advisory Partners as Strategic Advisors for National Exchange Listing and 3CL Pharma Spinoff
Jun. 21, 2022
Todos Medical Completes Validation of 27 Pathogen UTI PCR Panel at Its CLIA/CAP Laboratory Provista Diagnostics
Jun. 13, 2022
Todos Medical Reports Day 45 Update for Case Study #6
Jun. 10, 2022
Todos Medical Reports Day 28 Update for Case Study #5 with Erectile Dysfunction
Jun. 07, 2022
Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial vs. Amyloid PET
Jun. 03, 2022
Todos Medical Reports Day 26 Update For Case Study #4
Jun. 01, 2022
Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference
May 27, 2022
Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient
May 06, 2022
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength Including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
May 02, 2022
Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022
Apr. 27, 2022
Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics
Apr. 21, 2022
Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study
Apr. 20, 2022
Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid by LGC Group
Apr. 19, 2022
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label
Apr. 06, 2022
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
Apr. 04, 2022
Todos Medical Reports Case Study of Patient with Long COVID
Mar. 31, 2022
Billy Blanks® Endorses Todos Medical’s Line of Tollovid® Products
Mar. 28, 2022
Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma
Mar. 16, 2022
Todos Medical Appoints Greg Meiselbach as Vice President of Government Affairs
Mar. 08, 2022
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients
Jan. 27, 2022
Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Jan. 24, 2022
Pepperdine University Hosts the 22nd Annual Celebrity Flag Football Challenge®, Presented by Todos Medical’s Tollovid®
Jan. 19, 2022
Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies
Jan. 18, 2022
Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022
Jan. 12, 2022
Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022
Jan. 10, 2022
Todos Medical Records Record Weekly COVID PCR Testing Volumes at Provista
Dec. 27, 2021
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer’s Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing
Dec. 23, 2021
Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States
Dec. 22, 2021
Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing
Dec. 20, 2021
Todos Medical Announces “Test & Tollovid®” Holiday Package for Atlanta Area at Provista Diagnostics
Dec. 17, 2021
Todos Medical to Host Key Opinion Leader Webinar Entitled Tollovir™: a Potential Treatment for Covid-19
Dec. 16, 2021
Todos Medical Enters 90-Day Extension of Agreement with Convertible Note Holders on Moratorium on Conversions of Convertible Notes
Dec. 13, 2021
Todos Medical Interview and Presentation on Benzinga's All Access Conference Live December 14th at 10:20 AM EST
Dec. 10, 2021
Todos Medical Announces 2 New COVID-19 PCR Testing Reference Lab Agreements for CLIA/CAP Lab Provista Diagnostics
Dec. 07, 2021
CEOs Presenting at the Emerging Growth Conference on December 8; Register Now
Dec. 07, 2021
Todos Medical to Present at Upcoming Emerging Growth Conference
Dec. 06, 2021
Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation
Dec. 02, 2021
Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant
Nov. 30, 2021
Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma
Nov. 29, 2021
Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece
Nov. 22, 2021
Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients
Nov. 19, 2021
Todos Medical Announces Tollovid® Products Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. Covering 30 Countries in Europe
Nov. 18, 2021
Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test
Nov. 17, 2021
Todos Medical’s Provista Laboratory to Boost Top Line Through New Atlanta-based Reference Lab Agreement for COVID PCR, cPass Neutralizing Antibody & Respiratory Pathogen Panel Tests
Nov. 16, 2021
Todos Medical Reports Third Quarter 2021 Business and Financial Results
Nov. 15, 2021
Todos Medical Sees Significant Ramp Up in COVID PCR Testing Volume at Its Provista CLIA/CAP Lab with New Automation in Place
Nov. 02, 2021
Todos Medical Announces 2nd Clinical Trial Site for Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Nov. 01, 2021
Todos Medical Announces Publication in Nature Neuroscience That Describes the Main Protease (3CL Protease) Causes Microvascular Brain Pathology
Oct. 25, 2021
Todos Medical Announces Publication in Journal of Clinical Virology Highlighting Clinical Utility of cPass Semi-Quantitative Neutralizing Antibody Test in SARS-CoV-2 Risk Assessment Post-Vaccination or Recovery from Infection
Oct. 21, 2021
Todos Medical to Conduct Webinar Highlighting the cPass SARS-COV-2 Neutralizing Antibody Test for AMDA, The Society for Post-Acute and Long-Term Care Medicine, on October 22, 2021 at 12:00 PM EDT
Oct. 14, 2021
Todos Medical Announces Positive Data in Hospitalized and Outpatient Setting for TolloTest™, a Novel SARS-CoV-2 3CL Protease Biomarker Assay
Oct. 06, 2021
Todos Medical Provides Update on COVID-19 Oral Antiviral 3CL Protease (Main Protease) Inhibitor Tollovir Clinical Development Program in Light of Molnupiravir Clinical Trial Data from Merck
Oct. 04, 2021
Todos Medical Announces Positive Observational Trial Results for Oral Antiviral 3CL Protease (MPro) Inhibitor Tollovir®
Sep. 30, 2021
Todos Medical Receives Approval by Amazon to Sell Immune Supplements Tollovid® & Tollovid Daily™
Sep. 27, 2021
Todos Medical Reports Second Quarter 2021 Financial Results
Fri, Sep. 24, 2021
UPDATE: Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
Sep. 24, 2021
Todos Medical Launches Tollovid Daily™ via Subscription at MyTollovid.com
Sep. 23, 2021
Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Oral Antiviral Drug Candidate Tollovir™
Sep. 20, 2021
Todos Medical Now Accepting Cryptocurrency for the Purchase of Tollovid® and Tollovid Daily™ Through Coinbase Commerce
Sep. 17, 2021
Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
Sep. 15, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of Combination COVID, Influenza A & B, RSV & hMPV Respiratory Panel Test
Sep. 01, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of High-Capacity SARS-CoV-2 Variant Testing Service Capable of Identifying Known Variants
Aug. 26, 2021
Todos Medical’s CLIA/CAP Lab Provista Enters Into Reference Lab Agreement with Meadowlands Diagnostics to Provide cPass Neutralizing Antibody Blood Testing for Quantifying and Monitoring Key COVID-19 Immunity Biomarkers
Aug. 24, 20211
Todos Medical Completes Validation of cPass Neutralizing Antibody Blood Test at Provista Diagnostics to Quantify and Monitor Key Biomarkers of COVID-19 Immunity
Aug. 23, 2021
Todos Medical CEO to Appear on Fox Business Network Varney & Company Today at 11:40am to Discuss the Company’s Launch of cPass Neutralizing Antibody Testing for Monitoring COVID-19 Immunity
Aug. 23, 2021
Update: Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Dietary Supplement Tollovid™
Aug. 05, 2021
Todos Medical Receipt Notice of Allowance from USPTO for 3CL Protease Inhibitor Dietary Supplement Tollovid™
Aug. 05, 2021
Todos Medical Makes Final Payment to Close Provista Diagnostics Acquisition
Aug. 02, 2021
Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir
Jul. 28, 2021
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Daily™ Including 3CL Protease Inhibitor Claim
Jul. 22, 2021
Todos Medical to Launch EUA Authorized cPass SARS-CoV-2 Neutralizing Antibody Kit Through Agreement with Fosun Pharma
Jul. 19, 2021
Todos Medical Appoints Ilanit Halperin, CPA as Corporate Controller
Jul. 07, 2021
Todos Medical Receives FDA Certificate of Free Sale for New 5-Day Tollovid Dosing Regimen
May 04, 2021
Todos Medical Launches Phase 2 Clinical Trial of Its Antiviral 3CL Protease Inhibitor NLC-V-01 (Tollovir) in Hospitalized COVID-19 Patients
Apr. 19, 2021
Todos Medical Receives Notice of Allowance from European Patent Office for Patent Application Covering Diagnosis of Cancer Using Proprietary Artificial Intelligence TBIA Immune Profiling Platform
Apr. 08, 2021
Todos Medical Completes Automation Equipment Installation and Training for Meadowlands Diagnostics
Apr. 01, 2021
Todos Medical Enters Into Distribution Partnership with Osang Healthcare for the GeneFinder Plus™ COVID-19 Plus RealAMP Kit in the United States
Mar. 30, 2021
Todos Medical Completes Automation Equipment Installation and Training for a Laboratory Client in Brooklyn, NY
Mar. 29, 2021
Todos Medical Enters Into Automation and Reagent Supply Agreement with MAJL Diagnostics
Mar. 23, 2021
Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021
Mar. 12, 2021
Todos Medical Applauds Senate and House Passage of the American Recovery Act
Mar. 11, 2021
Todos Medical Announces Strategic Investment by Yozma Group Korea
Jan. 25, 2021
Todos Medical Announces $4.8 Million in Sales for December 2020, a 50% Month Over Month Increase in Sales from November 2020
Jan. 11, 2021
Todos Medical Announces Agreement to Supply Natural Wellness Clinics with COVID-19 Testing Products to Support Initiatives in the Commonwealth of Kentucky
Dec. 23, 2020
Aditxt Signs Distribution Agreement with Todos Medical Ltd. For AditxtScore™ for COVID-19 Immune Monitoring Service
Dec. 14, 2020
Todos Medical Announces Commercial Launch of Proprietary 3CL Protease Inhibitor Dietary Supplement Tollovid™ at The Alchemist’s Kitchen
Dec. 07, 2020
Todos Medical Announces $3.2 Million in Sales for November 2020, a 269% Increase Sequential Month over Month Sales Growth from October 2020
Dec. 02, 2020
Todos Medical Provides Strategic Outlook
Dec. 01, 2020
Todos Medical Completes Installation of Lab Automation Equipment at Wisconsin Lab Client to Support COVID-19 PCR Testing
Nov. 24, 2020
Todos Medical Announces Positive In Vitro Data for Tollovid™ Confirming 3CL Protease Inhibition Mechanism of Action
Nov. 20, 2020
Todos Medical Announces Positive Initial Clinical Proof-of-Concept Data for a Rapid SARS-CoV-2 3CL Protease Detection Assay
Nov. 18, 2020
Todos Medical Announces Clinical Validation and National CLIA Certification for MOTO+PARA Mobile High Complexity Labs
Nov. 17, 2020
Todos Medical Announces $867,000 in Sales for October 2020
Nov. 12, 2020
Todos Medical Trademarks Tollovid for Dietary Supplement NLC-001 and Enters Into Private Label & Distribution Agreement With The Alchemists Kitchen
Oct. 29, 2020
Todos Medical Announces Instrument Validation Complete at MOTO+PARA Mobile Lab
Oct. 26, 2020
Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep Point-of-Care Covid-19 Antibody Tests
Oct. 22, 2020
Todos Medical Receives Notices of Allowance From the European Patent Office Covering Use of TBIA Cancer Platform to Detect Benign Colon Cancer
Oct. 20, 2020
Todos Medical Reports $2.0 Million in Revenue for the Third Quarter of 2020
Oct. 13, 2020
Todos Medical Enters into Exclusive COVID-19 Testing Supply Agreement with MOTO+PARA’s National Mobile CLIA Lab Partner Integrated Health
Oct. 07, 2020
Todos Medical Enters into Exclusive Branding and Distribution Agreement with Melbourne Biotech for 96 and 384 Well RT-PCR Machines in the United States
Sep. 30, 2020
Todos Medical Enters Into COVID-19 PCR Testing Implementation and Equipment Financing Partnership with AID Genomics
Sep. 25, 2020
Todos Medical Expands Existing Contract for COVID-19 PCR Testing Equipment & Supplies with Wisconsin-based Laboratory to $47.5 Million
Sep. 22, 2020
Todos Medical CEO Releases Letter to Shareholders
Sep. 18, 2020
3CL Protease Inhibitor NLC-001 Added to COVID-19-focused Joint Venture Between Todos Medical and NLC Pharma
Sep. 17, 2020
Todos Medical Expands Partnership with Care G.B. Plus for Proprietary TBIA Cancer Tests to Include Europe, Israel and Africa
Sep. 16, 2020
Todos Medical Announces Commercial Launch of Todos Branded COVID-19 qPCR Test Kits in the United States
Sep. 11, 2020
Todos Medical Announces August Sales of $1,190,000, Up 100% Compared with July
Sep. 03, 2020
Todos Medical Enters Into Partnership With Pangea for COVID-19 Testing and Contact Tracing
Sep. 02, 2020
Todos Medical Announces $23,760,000 Contract for COVID-19 PCR Testing Equipment & Supplies With Wisconsin-based Laboratory
Aug. 31, 2020
Todos Medical to Present at The LD 500 Virtual Conference
Aug. 31, 2020
Todos Medical Announces $4,500,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory
Aug. 27, 2020
Todos Medical Appoints Marsha Fontanive as VP of Sales and Chris Gross as VP of Sales Operations
Aug. 25, 2020
Todos Medical Announces $1.2 Million Contract for COVID-19 PCR Testing Equipment & Supplies with Texas-based Laboratory
Aug. 24, 2020
Todos Medical Announces $6,000,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory
Aug. 21, 2020
Todos Medical Announces Positive Proof-of-Concept Data for Novel 10-Minute Point-of-Care Saliva-based Test Detecting Active SARS-CoV-2 Infection
Aug. 17, 2020
Todos Medical Acquires Distribution Rights to SARS-CoV-2 Rapid Point-of-Care Antigen Test and Rapid Point-of-Care PCR Test
Aug. 14, 2020
Todos Medical Announces July Sales of COVID-19 Tests
Aug. 07, 2020
Todos Medical Announces Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
Aug. 06, 2020
Todos Medical Appoints Dr. Jorge Leon as Consulting Chief Medical and Scientific Officer of Infectious Disease and Oncology
Aug. 04, 2020
Pathnova Laboratories (PATHNOVA) Enters into Partnership to Commercialize Todos Medicals COVID-19 and Breast Cancer Tests in Singapore
Aug. 03, 2020
Todos Medical Completes Acquisition of Breakthrough Diagnostics, Gains Full Rights to the Alzheimer’s Blood Diagnostic LymPro™ Test from Amarantus
Jul. 28, 2020
Todos Medical Announces SARS-nCoV-19 Testing Kit Contract with NJ-Based Best Supply Clinical Laboratory
Jul. 27, 2020
Todos Medical Expands Management Team and Advisory Board
Jul. 20, 2020
Todos Medical Announces ANVISA Authorization in Brazil for 3D Med qPCR Kits and ANDis Extraction S
Jul. 16, 2020
Saaweeeet….!
easy $$$ for even the novice investor - no brained here folks
BAF MONI…!
Beyon con on X
either a Gerald pathetic dreamer lap dawg or …
just another “under water” TOMDF shareholder …
praying for a financial reversal miracle …
and Gerald - with the forever “just around the corner” empty promises…
while the already financially destitute shareholders hang by a thread
2.8-Bil AS already printed - from TOMDF’s printing press
with more shares to dilute to support theses overbloated exec salaries
no hating - just keeping it real brah
SMH - what a shame …!
MOO sad
not you ..
the twerp you were replying too…lolzzz
BAF MONI
my spread is paid for
as is my retirement condo in FL
and its so much nicer than you living at home with your mother like you
living in her basement and on a fixed allowance...lolzzz
just saying - for my friend Vincent Vega - of course
https://imagizer.imageshack.com/v2/1600x1200q70/922/1CHjaE.jpg
SMH - sad but true
MOO dunce
$0.0031 to $0.0353 says it all
nice post sir
MONI making coin - about to splode
BAF MONI…!
COVID Schmovid…
TOMDF’s pathetic and paultry pps is all that matters…
SMH - nuff said…!
MOO hooie
TOMDF printing $0.0003
all the “reward” you have to celebrate…
SMH - sad but true…!
MOO stoopid
what’s the share count this week….?
SMH - dilution city
OEM
Epic … moves on thin air
BAF MONI …!
so far - all of these have proven to be total Gerald shite
Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics
Mar. 28, 2023
Todos Medical Begins Trading on the OTC Pink Marketplace
Mar. 27, 2023
Todos Medical Supports Long COVID Awareness Day
Mar. 15, 2023
Todos Medical Enters Into Moratorium on Conversions Agreement With Convertible Note Holders
Mar. 13, 2023
Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics
Feb. 14, 2023
Todos Medical to Present at the RHK 2022 Disruptive Growth Conference
Dec. 06, 2022
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
Nov. 29, 2022
Todos Medical to Attend World Antiviral Congress
Nov. 22, 2022
Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network
Nov. 16, 2022
Todos Medical Terminates Tollovid™ Products License & Distribution Agreement with T-Cell Protect Hellas S.A.
Nov. 10, 2022
Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for MonkeyPox PCR Test to US FDA
Oct. 14, 2022
Todos Medical Announces Successful Pilot Launch of Suite of PCR Testing Services by CLIA/CAP Lab Provista Diagnostics
Oct. 06, 2022
Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform
Sep. 30, 2022
Todos Medical Announces USPTO Trademark Notice of Allowance for 3CL Protease Biomarker Diagnostics TolloTest™
Sep. 27, 2022
Todos Medical Enters Into $50M Contract to Supply Tollovid™ and CBD Products to Retail Distributor Company Nerd Hemp
Sep. 22, 2022
Todos Medical Announces NFL Hall of Famer Michael Irvin as Tollovid™ Sports Ambassador for #TolloUp Campaign
Sep. 16, 2022
Todos Medical Announces Preprint of Long COVID Case Study Participant with Confirmed Microclot and Hyperactivated Platelets who Benefitted from Tollovid
Sep. 15, 2022
Todos Medical & The Alchemist’s Kitchen to Host “Long COVID: An Integrated Approach” Event Benefitting Survivor Corps
Sep. 13, 2022
Todos Medical’s 3CL Protease Inhibitor Supplement Tollovid™ Featured in Wellness Magazine
Sep. 13, 2022
Todos Medical Partner NLC Pharma Assigns IP for Tollovir™, Tollovid™, and TolloTest™ into JV 3CL Pharma
Sep. 12, 2022
Todos Medical CEO Discusses Long COVID Economic Impact with Moneta Advisory Managing Partner Marc LoPresti
Sep. 09, 2022
Todos Medical Announce Kingcarlx as Brand Ambassador for the Tollovid #TolloUp Lifestyle Campaign
Sep. 02, 2022
Todos Medical Establishes Botanical Supplement Manufacturing Capabilities to Support Tollovid Global Expansion and Initiates CBD-A Production
Aug. 31, 2022
Todos Medical Expands COVID Onsite School Sample Collection to Include MonkeyPox Testing
Aug. 29, 2022
Todos Medical Announces Saliva-Only MonkeyPox Testing at CLIA/CAP Clinical Lab Provista Diagnostics
Aug. 26, 2022
Todos Medical Enrolls Female Long COVID Patient Unable to Secure Testing While Symptomatic for MonkeyPox into Provista Diagnostics Case Study Series
Aug. 25, 2022
Todos Medical Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women
Aug. 23, 2022
Todos Medical Announces Commercialization of Lesion and Saliva-Based MonkeyPox PCR Testing
Aug. 22, 2022
Todos Medical Announces Preprint of Data from First 100 Participants in IRB-waived Market Research Study of Supplementation with Tollovid in Long COVID
Aug. 19, 2022
Todos Medical Reports Pre-Print of Publication Detailing Tollovid Supplementation Following COVID-19 mRNA Vaccination in Long COVID
Aug. 15, 2022
Todos Medical Completes Trial Design for Tollovid™ Long COVID Clinical Study in Adults
Aug. 11, 2022
Todos Medical Announces PCR Validation of Wound and Respiratory Pathogen Panels at CLIA/CAP Lab Provista Diagnostics
Aug. 10, 2022
Todos Medical Announces First Two Contracts for PCR-based MonkeyPox Testing at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
Aug. 08, 2022
Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics
Aug. 05, 2022
Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
Aug. 03, 2022
Todos Medical Announces Preprint of Acute COVID-19 Paxlovid Rebound Rescued by Tollovid
Aug. 01, 2022
Todos Medical Partners with Amerimmune Diagnostics on Long COVID Biomarker Panel
Jul. 28, 2022
Todos Medical Announces Preprint of Chronic Long COVID Case Study #8 of Paxlovid® Treatment Followed by Tollovid™ Dietary Supplementation
Jul. 22, 2022
Todos Medical Reports Case Study #7 in Acute and Long COVID
Jul. 12, 2022
Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients
Jun. 30, 2022
Todos Medical Releases Preliminary Data From IRB-Waived Tollovid® Market Research Study in Acute and Long COVID
Jun. 23, 2022
Todos Medical Retains Moneta Advisory Partners as Strategic Advisors for National Exchange Listing and 3CL Pharma Spinoff
Jun. 21, 2022
Todos Medical Completes Validation of 27 Pathogen UTI PCR Panel at Its CLIA/CAP Laboratory Provista Diagnostics
Jun. 13, 2022
Todos Medical Reports Day 45 Update for Case Study #6
Jun. 10, 2022
Todos Medical Reports Day 28 Update for Case Study #5 with Erectile Dysfunction
Jun. 07, 2022
Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial vs. Amyloid PET
Jun. 03, 2022
Todos Medical Reports Day 26 Update For Case Study #4
Jun. 01, 2022
Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference
May 27, 2022
Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient
May 06, 2022
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength Including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
May 02, 2022
Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022
Apr. 27, 2022
Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics
Apr. 21, 2022
Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study
Apr. 20, 2022
Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid by LGC Group
Apr. 19, 2022
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label
Apr. 06, 2022
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
Apr. 04, 2022
Todos Medical Reports Case Study of Patient with Long COVID
Mar. 31, 2022
Billy Blanks® Endorses Todos Medical’s Line of Tollovid® Products
Mar. 28, 2022
Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma
Mar. 16, 2022
Todos Medical Appoints Greg Meiselbach as Vice President of Government Affairs
Mar. 08, 2022
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients
Jan. 27, 2022
Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Jan. 24, 2022
Pepperdine University Hosts the 22nd Annual Celebrity Flag Football Challenge®, Presented by Todos Medical’s Tollovid®
Jan. 19, 2022
Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies
Jan. 18, 2022
Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022
Jan. 12, 2022
Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022
Jan. 10, 2022
Todos Medical Records Record Weekly COVID PCR Testing Volumes at Provista
Dec. 27, 2021
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer’s Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing
Dec. 23, 2021
Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States
Dec. 22, 2021
Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing
Dec. 20, 2021
Todos Medical Announces “Test & Tollovid®” Holiday Package for Atlanta Area at Provista Diagnostics
Dec. 17, 2021
Todos Medical to Host Key Opinion Leader Webinar Entitled Tollovir™: a Potential Treatment for Covid-19
Dec. 16, 2021
Todos Medical Enters 90-Day Extension of Agreement with Convertible Note Holders on Moratorium on Conversions of Convertible Notes
Dec. 13, 2021
Todos Medical Interview and Presentation on Benzinga's All Access Conference Live December 14th at 10:20 AM EST
Dec. 10, 2021
Todos Medical Announces 2 New COVID-19 PCR Testing Reference Lab Agreements for CLIA/CAP Lab Provista Diagnostics
Dec. 07, 2021
CEOs Presenting at the Emerging Growth Conference on December 8; Register Now
Dec. 07, 2021
Todos Medical to Present at Upcoming Emerging Growth Conference
Dec. 06, 2021
Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation
Dec. 02, 2021
Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant
Nov. 30, 2021
Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma
Nov. 29, 2021
Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece
Nov. 22, 2021
Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients
Nov. 19, 2021
Todos Medical Announces Tollovid® Products Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. Covering 30 Countries in Europe
Nov. 18, 2021
Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test
Nov. 17, 2021
Todos Medical’s Provista Laboratory to Boost Top Line Through New Atlanta-based Reference Lab Agreement for COVID PCR, cPass Neutralizing Antibody & Respiratory Pathogen Panel Tests
Nov. 16, 2021
Todos Medical Reports Third Quarter 2021 Business and Financial Results
Nov. 15, 2021
Todos Medical Sees Significant Ramp Up in COVID PCR Testing Volume at Its Provista CLIA/CAP Lab with New Automation in Place
Nov. 02, 2021
Todos Medical Announces 2nd Clinical Trial Site for Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Nov. 01, 2021
Todos Medical Announces Publication in Nature Neuroscience That Describes the Main Protease (3CL Protease) Causes Microvascular Brain Pathology
Oct. 25, 2021
Todos Medical Announces Publication in Journal of Clinical Virology Highlighting Clinical Utility of cPass Semi-Quantitative Neutralizing Antibody Test in SARS-CoV-2 Risk Assessment Post-Vaccination or Recovery from Infection
Oct. 21, 2021
Todos Medical to Conduct Webinar Highlighting the cPass SARS-COV-2 Neutralizing Antibody Test for AMDA, The Society for Post-Acute and Long-Term Care Medicine, on October 22, 2021 at 12:00 PM EDT
Oct. 14, 2021
Todos Medical Announces Positive Data in Hospitalized and Outpatient Setting for TolloTest™, a Novel SARS-CoV-2 3CL Protease Biomarker Assay
Oct. 06, 2021
Todos Medical Provides Update on COVID-19 Oral Antiviral 3CL Protease (Main Protease) Inhibitor Tollovir Clinical Development Program in Light of Molnupiravir Clinical Trial Data from Merck
Oct. 04, 2021
Todos Medical Announces Positive Observational Trial Results for Oral Antiviral 3CL Protease (MPro) Inhibitor Tollovir®
Sep. 30, 2021
Todos Medical Receives Approval by Amazon to Sell Immune Supplements Tollovid® & Tollovid Daily™
Sep. 27, 2021
Todos Medical Reports Second Quarter 2021 Financial Results
Fri, Sep. 24, 2021
UPDATE: Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
Sep. 24, 2021
Todos Medical Launches Tollovid Daily™ via Subscription at MyTollovid.com
Sep. 23, 2021
Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Oral Antiviral Drug Candidate Tollovir™
Sep. 20, 2021
Todos Medical Now Accepting Cryptocurrency for the Purchase of Tollovid® and Tollovid Daily™ Through Coinbase Commerce
Sep. 17, 2021
Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
Sep. 15, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of Combination COVID, Influenza A & B, RSV & hMPV Respiratory Panel Test
Sep. 01, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of High-Capacity SARS-CoV-2 Variant Testing Service Capable of Identifying Known Variants
Aug. 26, 2021
Todos Medical’s CLIA/CAP Lab Provista Enters Into Reference Lab Agreement with Meadowlands Diagnostics to Provide cPass Neutralizing Antibody Blood Testing for Quantifying and Monitoring Key COVID-19 Immunity Biomarkers
Aug. 24, 20211
Todos Medical Completes Validation of cPass Neutralizing Antibody Blood Test at Provista Diagnostics to Quantify and Monitor Key Biomarkers of COVID-19 Immunity
Aug. 23, 2021
Todos Medical CEO to Appear on Fox Business Network Varney & Company Today at 11:40am to Discuss the Company’s Launch of cPass Neutralizing Antibody Testing for Monitoring COVID-19 Immunity
Aug. 23, 2021
Update: Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Dietary Supplement Tollovid™
Aug. 05, 2021
Todos Medical Receipt Notice of Allowance from USPTO for 3CL Protease Inhibitor Dietary Supplement Tollovid™
Aug. 05, 2021
Todos Medical Makes Final Payment to Close Provista Diagnostics Acquisition
Aug. 02, 2021
Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir
Jul. 28, 2021
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Daily™ Including 3CL Protease Inhibitor Claim
Jul. 22, 2021
Todos Medical to Launch EUA Authorized cPass SARS-CoV-2 Neutralizing Antibody Kit Through Agreement with Fosun Pharma
Jul. 19, 2021
Todos Medical Appoints Ilanit Halperin, CPA as Corporate Controller
Jul. 07, 2021
Todos Medical Receives FDA Certificate of Free Sale for New 5-Day Tollovid Dosing Regimen
May 04, 2021
Todos Medical Launches Phase 2 Clinical Trial of Its Antiviral 3CL Protease Inhibitor NLC-V-01 (Tollovir) in Hospitalized COVID-19 Patients
Apr. 19, 2021
Todos Medical Receives Notice of Allowance from European Patent Office for Patent Application Covering Diagnosis of Cancer Using Proprietary Artificial Intelligence TBIA Immune Profiling Platform
Apr. 08, 2021
Todos Medical Completes Automation Equipment Installation and Training for Meadowlands Diagnostics
Apr. 01, 2021
Todos Medical Enters Into Distribution Partnership with Osang Healthcare for the GeneFinder Plus™ COVID-19 Plus RealAMP Kit in the United States
Mar. 30, 2021
Todos Medical Completes Automation Equipment Installation and Training for a Laboratory Client in Brooklyn, NY
Mar. 29, 2021
Todos Medical Enters Into Automation and Reagent Supply Agreement with MAJL Diagnostics
Mar. 23, 2021
Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021
Mar. 12, 2021
Todos Medical Applauds Senate and House Passage of the American Recovery Act
Mar. 11, 2021
Todos Medical Announces Strategic Investment by Yozma Group Korea
Jan. 25, 2021
Todos Medical Announces $4.8 Million in Sales for December 2020, a 50% Month Over Month Increase in Sales from November 2020
Jan. 11, 2021
Todos Medical Announces Agreement to Supply Natural Wellness Clinics with COVID-19 Testing Products to Support Initiatives in the Commonwealth of Kentucky
Dec. 23, 2020
Aditxt Signs Distribution Agreement with Todos Medical Ltd. For AditxtScore™ for COVID-19 Immune Monitoring Service
Dec. 14, 2020
Todos Medical Announces Commercial Launch of Proprietary 3CL Protease Inhibitor Dietary Supplement Tollovid™ at The Alchemist’s Kitchen
Dec. 07, 2020
Todos Medical Announces $3.2 Million in Sales for November 2020, a 269% Increase Sequential Month over Month Sales Growth from October 2020
Dec. 02, 2020
Todos Medical Provides Strategic Outlook
Dec. 01, 2020
Todos Medical Completes Installation of Lab Automation Equipment at Wisconsin Lab Client to Support COVID-19 PCR Testing
Nov. 24, 2020
Todos Medical Announces Positive In Vitro Data for Tollovid™ Confirming 3CL Protease Inhibition Mechanism of Action
Nov. 20, 2020
Todos Medical Announces Positive Initial Clinical Proof-of-Concept Data for a Rapid SARS-CoV-2 3CL Protease Detection Assay
Nov. 18, 2020
Todos Medical Announces Clinical Validation and National CLIA Certification for MOTO+PARA Mobile High Complexity Labs
Nov. 17, 2020
Todos Medical Announces $867,000 in Sales for October 2020
Nov. 12, 2020
Todos Medical Trademarks Tollovid for Dietary Supplement NLC-001 and Enters Into Private Label & Distribution Agreement With The Alchemists Kitchen
Oct. 29, 2020
Todos Medical Announces Instrument Validation Complete at MOTO+PARA Mobile Lab
Oct. 26, 2020
Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep Point-of-Care Covid-19 Antibody Tests
Oct. 22, 2020
Todos Medical Receives Notices of Allowance From the European Patent Office Covering Use of TBIA Cancer Platform to Detect Benign Colon Cancer
Oct. 20, 2020
Todos Medical Reports $2.0 Million in Revenue for the Third Quarter of 2020
Oct. 13, 2020
Todos Medical Enters into Exclusive COVID-19 Testing Supply Agreement with MOTO+PARA’s National Mobile CLIA Lab Partner Integrated Health
Oct. 07, 2020
Todos Medical Enters into Exclusive Branding and Distribution Agreement with Melbourne Biotech for 96 and 384 Well RT-PCR Machines in the United States
Sep. 30, 2020
Todos Medical Enters Into COVID-19 PCR Testing Implementation and Equipment Financing Partnership with AID Genomics
Sep. 25, 2020
Todos Medical Expands Existing Contract for COVID-19 PCR Testing Equipment & Supplies with Wisconsin-based Laboratory to $47.5 Million
Sep. 22, 2020
Todos Medical CEO Releases Letter to Shareholders
Sep. 18, 2020
3CL Protease Inhibitor NLC-001 Added to COVID-19-focused Joint Venture Between Todos Medical and NLC Pharma
Sep. 17, 2020
Todos Medical Expands Partnership with Care G.B. Plus for Proprietary TBIA Cancer Tests to Include Europe, Israel and Africa
Sep. 16, 2020
Todos Medical Announces Commercial Launch of Todos Branded COVID-19 qPCR Test Kits in the United States
Sep. 11, 2020
Todos Medical Announces August Sales of $1,190,000, Up 100% Compared with July
Sep. 03, 2020
Todos Medical Enters Into Partnership With Pangea for COVID-19 Testing and Contact Tracing
Sep. 02, 2020
Todos Medical Announces $23,760,000 Contract for COVID-19 PCR Testing Equipment & Supplies With Wisconsin-based Laboratory
Aug. 31, 2020
Todos Medical to Present at The LD 500 Virtual Conference
Aug. 31, 2020
Todos Medical Announces $4,500,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory
Aug. 27, 2020
Todos Medical Appoints Marsha Fontanive as VP of Sales and Chris Gross as VP of Sales Operations
Aug. 25, 2020
Todos Medical Announces $1.2 Million Contract for COVID-19 PCR Testing Equipment & Supplies with Texas-based Laboratory
Aug. 24, 2020
Todos Medical Announces $6,000,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory
Aug. 21, 2020
Todos Medical Announces Positive Proof-of-Concept Data for Novel 10-Minute Point-of-Care Saliva-based Test Detecting Active SARS-CoV-2 Infection
Aug. 17, 2020
Todos Medical Acquires Distribution Rights to SARS-CoV-2 Rapid Point-of-Care Antigen Test and Rapid Point-of-Care PCR Test
Aug. 14, 2020
Todos Medical Announces July Sales of COVID-19 Tests
Aug. 07, 2020
Todos Medical Announces Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
Aug. 06, 2020
Todos Medical Appoints Dr. Jorge Leon as Consulting Chief Medical and Scientific Officer of Infectious Disease and Oncology
Aug. 04, 2020
Pathnova Laboratories (PATHNOVA) Enters into Partnership to Commercialize Todos Medicals COVID-19 and Breast Cancer Tests in Singapore
Aug. 03, 2020
Todos Medical Completes Acquisition of Breakthrough Diagnostics, Gains Full Rights to the Alzheimer’s Blood Diagnostic LymPro™ Test from Amarantus
Jul. 28, 2020
Todos Medical Announces SARS-nCoV-19 Testing Kit Contract with NJ-Based Best Supply Clinical Laboratory
Jul. 27, 2020
Todos Medical Expands Management Team and Advisory Board
Jul. 20, 2020
Todos Medical Announces ANVISA Authorization in Brazil for 3D Med qPCR Kits and ANDis Extraction S
Jul. 16, 2020
resorting to medication are you...?
can't win fair and square - eh
here's all the "REALITY" you have to know "JOEFORKEYBOLO" "WORDMAN" "REDSPEED" whoever the hell you are...!
Printing $0.0003
10-Bil. AS, 2.7-Bil. AS and climbing weekly, and a preapproved massive 1:500 RS on tap
SMH - you're all the same - keep pumping this shite...!
AJMHO
oh so now JoeForkeyBolo has a PM smokescreen to Redspeed
so JFB is Redspeed too - wow how many fake aliases do you have brah...?
interesting that Wordman starts posting the very same time that you do - are you Wordman too...?
what a fake you and the other fake alias Back Office Promo Boys are...
SMH - nothing but a bunch of shills, touts, dolts, pumpers and tools - LMAO
MOO hooie
yeah I lost nice coin in AMBS - no doubt
I've never disputed it - or that MANF was the reason why I invested
but my loss was on BREACH - get you facts straight little boy
additionally I have never sold 1 AMBS share
but you on the other hand lost mega $$$ in AMBS, and repeated it again in TOMDF
now why is that - are you a shill & tout working for the Back Office Promo Boyzzzz
sure does apprear that way - eh "JOEY"...?
WTF JFB fake little boy - or is it WarpCore - wink wink
MOO dumb
AJMHO
you got your AMBS "facts" about me all scewed brah...!
every time you post - you're wrong - I'm LMFAO
that's why I continue to take you apart - like a fine tune mechanic - breaking down a shit engine...!
continue to be the little boy that you are - with a multiple aliases, fake IP addresses, and burner phones
and a stick-on fake grown-up mustache - pretending like you're all grown up - and living in a grown-ups world...!
MOO dufus
yeah OK "Joey"
you can use my real name - all the while remaining incognito and hiding behind your keyboard with your multiple fake aliases, burner phones, and phony IP addresses - just like a little boy hiding
you and your Back Office Promo Boy 'wrecking crew' are nothing more that dolts, touts and shills
destroying the lives of others - with your non-stop continual pumping of your twice failed scam artist CEO and his toxic death spiral funded non-reporting shells
you can make fun of me and my family members - and make sophomoric jokes about me and them on social media platforms all over the internet
you can continue to order Dominos pizza's and have them delivered pizza's to my home - they'll just monitor your fake IP addresses and record those transactions and will eventually find you
you can even send messages to my employer about how you feel I'm a bigot or a racist - they'll only document who you and the others are - not too smart there - eh Joey - I go all the way back to 1992 with them - how far back do you go - kinda stoopid if you ask me - eh "JOEY" - you really want to be on "their" radar screen...?
all of your failed efforts to discredit me and my family members do not change the facts that you were warned countless times about the heinous motives of TOMDF & AMBS and their CEO
including their notorious Astoria Queens toxic death spiral financial interests - which suit both side of the 'double win' financial coin - all at SH's expense
almost 3% of the entire float (if you actually do own that much), makes you a catastrophic looser in touting this scam OTC stinky pinky
but then again, maybe that was you and your Back Office Promo Boy purposed along, eh "JOEY"
to separate SH's from their hard earned dollars and to put it into the pockets of your illustrious man-crush CEO...?
SMH - very probably sad but true..
AJMHO
TOMDF printing $0.0003
"We understand the Financial Engineering"
Gerald Commissiong - TOMDF twice failed, hack, wannabe, Stanford University Financial Engineering graduate and toxic death spiral convertible orchestrator CEO
would you trust this CEO scam artist or JoeForkeyBolo, Maui, Wordman, GreeseMonkey, Gman, Redspeed, or any other Back Office Promo Boyzzz touts and shills with you or your family's hard earned honest money? I don't think so...!
SMH - nothing more than Gerald shit - nuff said
this is all you truly have to know "Joey" boy
MOO scam